More Blogs
- Selling the Disease Before the Drug: How Unbranded “Awareness” Advertising Escapes the Rules Written to Protect Patients
- The Hormone in the Label’s Blind Spot: Why Risperdal and Zyprexa Breast Cancer Claims Have the Makings of a Mass Tort
- A Factory Without Smokestacks: Why New Mexico’s $942 Million Judgment Against Meta Is Bigger Than the Number
- When the Product Is the Predator’s Accomplice: The Snapchat Lawsuit That Could Redefine Platform Liability
- Three Bankruptcies, Ten Years, $5.5 Billion: The Anatomy of Johnson & Johnson’s Talc Settlement
